Literature DB >> 29622532

Blinatumomab for MRD+ B-ALL: the evidence strengthens.

Patrick Brown1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29622532     DOI： 10.1182/blood-2018-02-830364

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

Review 1.  Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery.

Authors:  Marcus J C Long; Dziyana Hnedzko; Bo Kyoung Kim; Yimon Aye
Journal:  Chembiochem       Date:  2019-04-01       Impact factor: 3.164

2.  Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.

Authors:  Swantje Buchmann; Martin Schrappe; Andre Baruchel; Andrea Biondi; Michael Borowitz; Myriam Campbell; Gunnar Cario; Giovanni Cazzaniga; Gabriele Escherich; Christine J Harrison; Mats Heyman; Stephen P Hunger; Csongor Kiss; Hsi-Che Liu; Franco Locatelli; Mignon L Loh; Atsushi Manabe; Georg Mann; Rob Pieters; Ching-Hon Pui; Susana Rives; Kjeld Schmiegelow; Lewis B Silverman; Jan Stary; Ajay Vora; Patrick Brown
Journal:  Blood       Date:  2022-03-24       Impact factor: 22.113

Review 3.  Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.

Authors:  Dain Moon; Nara Tae; Yunji Park; Seung-Woo Lee; Dae Hee Kim
Journal:  Immune Netw       Date:  2022-02-14       Impact factor: 5.851
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.